Effects of fexofenadine on the early response to nasal allergen challenge

被引:19
作者
Allocco, FT [1 ]
Votypka, V [1 ]
deTineo, M [1 ]
Naclerio, RM [1 ]
Baroody, FM [1 ]
机构
[1] Univ Chicago, Pritzker Sch Med, Sect Otolaryngol Head & Neck Surg, Chicago, IL 60637 USA
关键词
D O I
10.1016/S1081-1206(10)62105-9
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: Previous studies using nasal allergen challenge models have shown that terfenadine, an H-1 antihistamine, inhibits histamine release during the early response to allergen provocation. Fexofenadine, the active metabolite of terfenadine, has strong H-1-antihistaminic activity and no cardiac effects. Clinical studies have documented the efficacy of fexofenadine in the treatment of allergic rhinitis. Objective: To determine whether fexofenadine, like terfenadine, inhibits histamine and tryptase release during the early allergic response. Methods: Randomized, double blind, placebo-controlled, two-way crossover study in 20 subjects with seasonal allergic rhinitis, out of their allergy season (median age 27.5 years, 13 males and 7 females). Subjects were medicated with either placebo or fexofenadine 180 mg orally daily for 1 week followed by nasal challenge with allergen. After each challenge, sneezes and nasal symptoms were recorded, and a nasal lavage was obtained for the assay of albumin, an indicator of vascular permeability, and histamine and tryptase, indicators of mast cell degranulation. Results: When patients were on placebo, allergen challenges led to significant increases in all measured parameters compared with the sham challenges with diluent. Treatment with fexofenadine resulted in inhibition of allergen-induced symptoms and increased vascular permeability, but not the release of histamine and tryptase. Conclusion: Fexofenadine is an effective H-1 antihistamine, but in contrast to its parent compound, terfenadine, it does not affect the release of the mast cell mediators histamine and tryptase.
引用
收藏
页码:578 / 584
页数:7
相关论文
共 25 条
[1]  
Baroody FM, 1996, ARCH OTOLARYNGOL, V122, P309
[2]  
BEAUVAIS F, 1992, J IMMUNOL, V148, P149
[3]   Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis [J].
Bernstein, DI ;
Schoenwetter, WF ;
Nathan, RA ;
Storms, W ;
Ahlbrandt, R ;
Mason, J .
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 1997, 79 (05) :443-448
[4]   Safety and efficacy of once-daily fexofenadine HCI in the treatment of autumn seasonal allergic rhinitis [J].
Casale, TB ;
Andrade, C ;
Qu, R .
ALLERGY AND ASTHMA PROCEEDINGS, 1999, 20 (03) :193-198
[5]   Low dose clemastine inhibits sneezing and rhinorrhea during the early nasal allergic reaction [J].
Chung, JH ;
deTineo, ML ;
Naclerio, RM ;
Sorrentino, JV ;
Winslow, CM ;
Baroody, FM .
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 1997, 78 (03) :307-312
[6]   TERFENADINE EXERTS ANTIALLERGIC ACTIVITY REDUCING ICAM-I EXPRESSION ON NASAL EPITHELIAL-CELLS IN PATIENTS WITH POLLEN ALLERGY [J].
CIPRANDI, G ;
PRONZATO, C ;
RICCA, V ;
VARESE, P ;
DELGIACCO, GS ;
CANONICA, GW .
CLINICAL AND EXPERIMENTAL ALLERGY, 1995, 25 (09) :871-878
[7]  
Ichinose M, 1995, METHOD FIND EXP CLIN, V17, P36
[8]   EFFECT OF OXYMETAZOLINE ON THE EARLY RESPONSE TO NASAL CHALLENGE WITH ANTIGEN [J].
MAJCHEL, AM ;
BAROODY, F ;
KAGEYSOBOTKA, A ;
LICHTENSTEIN, LM ;
NACLERIO, RM .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1993, 92 (05) :767-770
[9]   Once-daily fexofenadine HCl improves quality of life and reduces work and activity impairment in patients with seasonal allergic rhinitis [J].
Meltzer, EO ;
Casale, TB ;
Nathan, RA ;
Thompson, AK .
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 1999, 83 (04) :311-317
[10]  
NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597